Contact Us
  • Choose License Type

The global small molecule prefilled syringes market by Drug Class (Cardiovascular Drugs, Neurology Drugs, Analgesics, Adjuvants, and Others), By Material (Glass, and Plastic & Polymer), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 13,749.4 million in 2016 and is projected to exhibit a CAGR of 4.6% over the forecast period (2017–2025). 

Availability of wide number of small molecule prefilled syringe products (generic as well as branded), advantages over conventional dosage forms (instant effect) such as tablets and capsules, and increasing adoption of small molecule prefilled syringe products is expected to fuel growth of the small molecule prefilled syringes market. Manufacturers are focusing on capitalizing on patent losses to launch generic versions in the market. For instance, in 2017, Mylan N.V. launched generic alternative to Copaxone 40 mg/ml for multiple sclerosis patients in the U.S. Moreover, Mylan N.V. launched Brabio, first generic alternative to Copaxone 40 mg/ml, for multiple sclerosis patients in the U.K., in January 2018. Teva Pharmaceuticals enhanced presence in Multiple Sclerosis segment through the introduction of three-times-a-week Copaxone 40 mg/mL product in the U.S in 2014. In 2015, Teva Pharmaceuticals launched Generic Lovenox in the U.S. market. In 2016, Fresenius Kabi launched Ketorolac injection in its ready-to-administer prefilled glass syringe. Sandoz announced the U.S. Food & Drug Administration approval and launch of Glatopa (Glatiramer acetate) 40 mg/mL, in February 2018.

Browse 34 Market Data Tables and 55 Figures spread through 161 Pages and in-depth TOC on Small Molecule Prefilled Syringes Market by Drug Class (Cardiovascular Drugs, Neurology Drugs, Analgesics, Adjuvants, and Others), By Material (Glass, and Plastic & Polymer) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025.

To know the latest trends and insights prevalent in the small molecule prefilled syringes market, click the link below:

https://www.coherentmarketinsights.com/market-insight/small-molecule-prefilled-syringes-market-1629

Key players in the market are focusing on collaborations, acquisitions, and partnerships, in order to enhance their market share. For instance, in 2013, Unilife Corporation entered into a long term supply contract with Sanofi S.A. The objective was to use Unilife’s Unifill Finesse platform of prefilled syringes with Sanofi S.A.’s Enoxaparin Sodium sold under brand names, Lovenox and Clexane. Pfizer, Inc. acquired Hospira, Inc. in the year 2015. Hospira, Inc. was a leading provider of injectable drugs and infusion technologies and this is expected to aid the company in increasing its market share. In 2016, Fresenius Kabi USA acquired BD Rx business from Becton, Dickinson, and Company. The business included pharmaceutical manufacturing plant and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes.

Key Takeaways of the Small Molecule Prefilled Syringes Market:

  • The global small molecule prefilled syringes market is expected to exhibit a CAGR of 6% over the forecast period (2017–2025), owing to increasing product launches by manufacturers such as Mylan N.V., and Fresenius Kabi, AG in this prefilled syringes
  • Availability of small molecule therapies in neurology segment is very low and therefore, the segment has high growth potential
  • Major drugs in the neurology drugs segment such as Copaxone (manufactured by Teva Pharmaceutical Industries Ltd.) are expected to face competition from generics
  • Major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson, and Company, and Fresenius Kabi AG
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner